The Murmur Pod

Champion AF Explained: Can LAA Closure Beat DOACs? Ft. Dr. Saibal Kar and Dr. Tom Waggoner

36 min · 29 de abr de 2026
Portada del episodio Champion AF Explained: Can LAA Closure Beat DOACs? Ft. Dr. Saibal Kar and Dr. Tom Waggoner

Descripción

The Champion AF trial is one of the most important studies in structural heart — directly comparing left atrial appendage closure (LAAC) to DOAC therapy in patients with atrial fibrillation. In this MurmurMD discussion, Dr. Saibal Kar and Dr. Thomas Waggoner break down the Champion AF data, focusing on what the results actually mean for clinical practice and how they may shift long-term management strategies. Key themes from the transcript include: • The rationale behind comparing LAAC to DOAC therapy • Trial design and patient population • Key outcomes and how to interpret them • Safety and efficacy considerations • Where LAAC fits in the treatment algorithm today • How these results may impact future guidelines and patient selection This discussion offers a practical, real-world interpretation of a pivotal trial — and what it means for stroke prevention in atrial fibrillation moving forward. 🔔 Subscribe for more insights from interventional experts and real-world program builders. 📱 Download the app: https://apps.apple.com/app/apple-store/id1586692687 📺 Follow us on YouTube: https://www.youtube.com/channel/UCfrLYhAhliQ2ZvXinkDCZvA Chapters: 00:00 – Overview of Champion AF and why it matters 01:00 – Trial design and patient selection 03:00 – Key outcomes and results interpretation 05:30 – Safety and procedural considerations 07:00 – LAAC vs DOAC: how to think about it clinically 08:30 – What this means for practice and future direction #ChampionAF #LAAClosure #AtrialFibrillation #StrokePrevention #StructuralHeart #Watchman #InterventionalCardiology #MurmurMD

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de The Murmur Pod!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

49 episodios

episode How Transcatheter Arterialization of Deep Veins Saves Limbs with Dr. Vargas Estrada artwork

How Transcatheter Arterialization of Deep Veins Saves Limbs with Dr. Vargas Estrada

What happens when a patient has critical limb-threatening ischemia, severe calcification, no distal targets, and has failed traditional endovascular therapy? In this MurmurMD discussion, Dr. Andres Vargas Estrada and Dr. Sameh Sayfo explain the evolution of Deep Vein Arterialization (DVA/TADV) and why it has become a powerful option for patients previously considered "no-option" candidates. The conversation explores the changing landscape of peripheral artery disease, the rise of small artery disease and medial arterial calcification, and why conventional therapies often fail in advanced CLTI patients. Key topics include: • Why today's CLTI patients are different than those of the past • The impact of diabetes, dialysis, and severe calcification • Understanding the MAC score and predicting treatment failure • Why traditional tibial interventions often fall short • The role of vessel preparation before advanced therapies • How Javelin, IVL, and bioresorbable scaffolds fit into modern limb salvage • The history and evolution of Deep Vein Arterialization • How DVA reroutes blood flow to preserve limbs when no arterial options remain This discussion highlights one of the most innovative shifts in peripheral intervention: when arteries can't be reopened, use the veins. 🔔 Subscribe for more insights from interventional experts and real-world program builders. 📱 Download the app: https://apps.apple.com/app/apple-store/id1586692687 📺 Follow us on YouTube: https://www.youtube.com/channel/UCfrLYhAhliQ2ZvXinkDCZvA Chapters: 00:00 – Why CLTI remains one of the biggest challenges in vascular care 03:00 – The shift from large artery disease to small artery disease 05:00 – Using the MAC score to identify no-option patients 07:00 – Modern tools: Javelin, IVL, and bioresorbable scaffolds 10:00 – The origins and evolution of Deep Vein Arterialization 13:00 – How DVA works and why it can salvage limbs 18:00 – Patient selection and practical considerations 22:00 – Future directions in limb salvage #DeepVeinArterialization #DVA #CLTI #LimbSalvage #PeripheralArteryDisease #Endovascular #PeripheralIntervention #CriticalLimbIschemia #MurmurMD

Ayer56 min
episode Removing Intracardiac Masses Without Surgery: Transcatheter Techniques Explained artwork

Removing Intracardiac Masses Without Surgery: Transcatheter Techniques Explained

Intracardiac masses have traditionally meant high-risk surgery — but transcatheter approaches are changing what’s possible in structural and endovascular intervention. In this MurmurMD discussion, Dr. Abdallah El Sabbagh and Dr. Andrei Pop review the evolving role of transcatheter removal of intracardiac masses, focusing on procedural planning, imaging guidance, device strategy, and patient selection. Key discussion points from the transcript include: • Types of intracardiac masses considered for transcatheter removal • Imaging strategies for procedural planning and guidance • Access considerations and device positioning • Managing embolic risk during extraction • Technical challenges unique to intracardiac mass removal • Patient selection and procedural decision-making • Real-world lessons from complex intracardiac cases • The expanding role of minimally invasive intracardiac intervention This discussion provides a practical look at how transcatheter techniques are creating new options for managing intracardiac masses without open surgery. 🔔 Subscribe for more insights from interventional experts and real-world program builders. 📱 Download the app: https://apps.apple.com/app/apple-store/id1586692687 📺 Follow us on YouTube: https://www.youtube.com/channel/UCfrLYhAhliQ2ZvXinkDCZvA Chapters: 00:00 – Why transcatheter intracardiac mass removal is evolving 01:30 – Imaging and procedural planning 03:30 – Access strategy and device positioning 05:30 – Managing embolic risk and technical challenges 07:30 – Patient selection and case considerations 09:00 – Key lessons and future direction #StructuralHeart #IntracardiacMass #TranscatheterIntervention #InterventionalCardiology #CardiacImaging #Endovascular #MurmurMD

25 de may de 202627 min
episode How Top LAAO Programs Scale Faster: Efficiency, Workflow, and Growth Strategies artwork

How Top LAAO Programs Scale Faster: Efficiency, Workflow, and Growth Strategies

Building a successful LAAO program requires more than procedural skill — it depends on workflow efficiency, team coordination, and scalable systems. In this MurmurMD discussion, Dr. Vijay Iyer and Dr. Joe Walsh break down the key drivers behind LAAO program efficiency and growth, focusing on how high-performing programs optimize patient flow, referrals, procedural planning, and long-term expansion. Key discussion points from the transcript include: • Improving workflow efficiency in LAAO programs • Referral pathways and program growth strategies • Streamlining patient evaluation and scheduling • Building coordination across the heart team • Procedural efficiency and lab workflow optimization • Managing follow-up and longitudinal patient care • Identifying bottlenecks that slow program growth • Lessons learned from scaling successful LAAO programs This discussion provides practical insights into how structural heart teams can grow LAAO programs while improving efficiency and patient care. 🔔 Subscribe for more insights from interventional experts and real-world program builders. 📱 Download the app: https://apps.apple.com/app/apple-store/id1586692687 📺 Follow us on YouTube: https://www.youtube.com/channel/UCfrLYhAhliQ2ZvXinkDCZvA Chapters: 00:00 – Why LAAO program efficiency matters 01:30 – Referral pathways and program growth 03:30 – Streamlining workflow and patient evaluation 05:30 – Team coordination and procedural efficiency 07:30 – Managing follow-up and long-term care 09:00 – Lessons learned from scaling LAAO programs #LAAO #StructuralHeart #Watchman #LeftAtrialAppendageClosure #ProgramGrowth #HeartTeam #InterventionalCardiology #MurmurMD

14 de may de 202620 min
episode Real-World Reintervention Rates Among TAVR Low-Risk Medicare Patients with Dr. Robert Yeh and Dr. Matthew Summers artwork

Real-World Reintervention Rates Among TAVR Low-Risk Medicare Patients with Dr. Robert Yeh and Dr. Matthew Summers

As TAVR expands into younger and lower-risk patients, one question continues to drive decision-making: how durable are transcatheter valves over time? In this MurmurMD discussion, Dr. Robert W. Yeh reviews his late-breaker at CRT26, the Evolut valve durability data, focusing on long-term outcomes and what they mean for real-world clinical practice with Dr. Matthew Summers. Key insights from the transcript include: • Long-term performance of self-expanding Evolut valves • How durability is assessed and measured over time • Structural valve degeneration and clinical relevance • Comparing durability expectations in TAVR vs surgical valves • Patient selection and lifetime management considerations • What durability data means for younger TAVR patients • How evolving evidence may shape future practice This discussion provides a focused look at how durability data is influencing TAVR decision-making today and into the future. 🔔 Subscribe for more insights from interventional experts and real-world program builders. 📱 Download the app: https://apps.apple.com/app/apple-store/id1586692687 📺 Follow us on YouTube: https://www.youtube.com/channel/UCfrLYhAhliQ2ZvXinkDCZvA Chapters: 00:00 – Why valve durability matters in TAVR 01:00 – Overview of Evolut durability data 02:30 – Structural valve degeneration and outcomes 04:30 – Comparing TAVR vs surgical durability 06:00 – Clinical implications for patient selection 07:30 – Key takeaways and future direction #TAVR #Evolut #ValveDurability #StructuralHeart #AorticStenosis #InterventionalCardiology #MurmurMD

9 de may de 202628 min
episode When PCI Gets Dangerous: How LV Support Changes High-Risk Cases artwork

When PCI Gets Dangerous: How LV Support Changes High-Risk Cases

High-risk PCI isn’t just about technique — it’s about protecting the patient while you fix the artery. In this MurmurMD discussion, Dr. Chris Brown and Dr. Yousif Ahmad walk through the role of left ventricular (LV) support in complex PCI, focusing on when to escalate, how to think about hemodynamics, and why support can change the entire strategy. Key insights from the discussion include: • Identifying patients who qualify as high-risk PCI • Recognizing when hemodynamics may deteriorate during intervention • Deciding when to use LV support devices • How support changes procedural planning and execution • Balancing complete revascularization with patient stability • Real-time decision-making during complex cases • Lessons learned from managing high-risk coronary interventions This discussion highlights a critical shift in mindset: in high-risk PCI, success depends as much on support strategy as it does on technical skill. 🔔 Subscribe for more insights from interventional experts and real-world program builders. 📱 Download the app: https://apps.apple.com/app/apple-store/id1586692687 📺 Follow us on YouTube: https://www.youtube.com/channel/UCfrLYhAhliQ2ZvXinkDCZvA Chapters: 00:00 – What defines high-risk PCI 01:00 – Hemodynamic risk and patient selection 02:30 – When to escalate to LV support 04:00 – How support changes PCI strategy 06:00 – Procedural decision-making under support 07:30 – Outcomes and key takeaways #HighRiskPCI #LVSupport #ComplexPCI #MechanicalCirculatorySupport #InterventionalCardiology #CathLab #MurmurMD

2 de may de 202621 min